Whereas aggregation often quenches luminescence, the emission of a heterocyclic luminogen, 10-[2,5-bis(4-pentyloxyphenylcarbonyloxy)phenyl]-9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (3), is greatly enhanced by aggregate formation. Crystallization further boosts the emission of 3, turning it from a weak emitter in the solution state to a strong emitter in the crystalline state. The emission of 3 is changed in response to the exposure to vapors of volatile organic compounds (VOCs). The morphology of the thin film of 3 is reversibly and repeatedly modulated between amorphous and crystalline phases by simple fuming-heating and heating-cooling cycles, leading to an emission switching between bright and dark states. The novel attributes of the crystallization-induced emission enhancement, the VOC-responsive emission change, and the morphology-tunable emission switching of 3 could enable it to find applications in an array of technological areas, including chemosensing, optical display, and rewritable information storage.
No takes yet. Share an insight, caveat, or question.
Qian et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: